Ultra-rapid Idylla™ Mutation Screening Followed by Next-generation Sequencing: An Integrated Solution to Molecular Diagnosis of Non-small Cell Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 17

PMID 37064089

Authors

Tian Qiu

Fanshuang Zhang

Bo Zheng

Zitong Feng

Weihua Li

Hua Zeng

Lixia Chu

Jianming Ying

Affiliations

Soon will be listed here.

Abstract

Background: Rapid profiling of the mutations is crucial to help clinicians choose the optimal treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Unfortunately, current diagnostic techniques, including ARMS-PCR and NGS, generally require several days to deliver final results. This diagnostic delay may lead to treatment delays for patients who are worsening rapidly.

Methods: This study introduced the ultra-rapid Idylla™ system for rapid, sensitive and specific identification of the mutations among Chinese NSCLC patients. Idylla™ Assay, an integrated cartridge running on the Idylla™ system, which can detect 51 mutations directly from Formalin-Fixed, Paraffin-Embedded (FFPE) samples within 2.5 hours, was used in this study. The sensitivity and specificity of the Idylla™ system were evaluated in comparison with ARMS-PCR or NGS using 95 clinical samples.

Results: The Idylla™ system achieved a sensitivity of 97.6%, a specificity of 100%, and an overall concordance of 97.9% for 95 retrospective samples. When compared to ARMS-PCR, the Idylla™ system demonstrated high accuracy with an overall agreement of 97.1% (34/35), a sensitivity of 95.2% (20/21) (95% CI, 76.2% - 99.9%), and an estimated specificity of 100% (12/12) (95% CI, 76.8% - 100%) for 35 prospective samples.

Conclusions: This Idylla system provides a rapid, accurate and simple approach for screening mutations, which can guide Tyrosine Kinase Inhibitors (TKI) treatment for NSCLC patients in a timely manner.

References

Yu P, Vose J, Hayes D . Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity. J Clin Oncol. 2015; 33(31):3533-4. DOI: 10.1200/JCO.2015.63.3628. View

Li W, Qiu T, Guo L, Ying J . Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Cancer Lett. 2017; 410:92-99. DOI: 10.1016/j.canlet.2017.09.014. View

Fang S, Wang Z . EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther. 2014; 8:1595-611. PMC: 4189714. DOI: 10.2147/DDDT.S69690. View

Midha A, Dearden S, McCormack R . EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9):2892-911. PMC: 4633915. View

Liu J, Zhao R, Zhang J, Zhang J . ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens. J Cancer Res Clin Oncol. 2014; 141(2):221-7. DOI: 10.1007/s00432-014-1807-z. View

Lindeman N, Cagle P, Beasley M, Chitale D, Dacic S, Giaccone G . Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular.... J Thorac Oncol. 2013; 8(7):823-59. PMC: 4159960. DOI: 10.1097/JTO.0b013e318290868f. View

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

de Montpreville V, Ghigna M, Lacroix L, Lemoine A, Besse B, Mercier O . EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Pathol Res Pract. 2017; 213(7):793-798. DOI: 10.1016/j.prp.2017.03.011. View

10.

De Luca C, Conticelli F, Leone A, Gragnano G, Salatiello M, Galasso P . Is the Idylla Mutation Assay feasible on archival stained cytological smears? A pilot study. J Clin Pathol. 2019; 72(9):609-614. DOI: 10.1136/jclinpath-2019-205863. View

11.

Evrard S, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos Y . Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer. J Mol Diagn. 2019; 21(6):1010-1024. DOI: 10.1016/j.jmoldx.2019.06.010. View

12.

OKane G, Bradbury P, Feld R, Leighl N, Liu G, Pisters K . Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017; 109:137-144. DOI: 10.1016/j.lungcan.2017.04.016. View

13.

Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y . Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer. 2015; 89(3):337-42. DOI: 10.1016/j.lungcan.2015.06.008. View

14.

Ahn M, Tsai C, Shepherd F, Bazhenova L, Sequist L, Hida T . Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2018; 125(6):892-901. DOI: 10.1002/cncr.31891. View

15.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View

16.

Yasuda H, Park E, Yun C, Sng N, Lucena-Araujo A, Yeo W . Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013; 5(216):216ra177. PMC: 3954775. DOI: 10.1126/scitranslmed.3007205. View

17.

De Luca C, Rappa A, Gragnano G, Malapelle U, Troncone G, Barberis M . Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. J Clin Pathol. 2018; 71(8):745-750. DOI: 10.1136/jclinpath-2018-205197. View

18.

Tu H, Ke E, Yang J, Sun Y, Yan H, Zheng M . A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017; 114:96-102. DOI: 10.1016/j.lungcan.2017.11.005. View

19.

Ramalingam S, Yang J, Lee C, Kurata T, Kim D, John T . Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2017; 36(9):841-849. DOI: 10.1200/JCO.2017.74.7576. View

20.

Gainor J, Shaw A . Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013; 31(31):3987-96. PMC: 3805932. DOI: 10.1200/JCO.2012.45.2029. View